Foetal lipoprotein oxidation and preeclampsia

L A Gil-Acevedo1,2, Guillermo Ceballos3, Y D Torres-Ramos4

  • 1Laboratorio Central, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, Secretaría de Salud, Montes Urales 800, Lomas Virreyes, Miguel Hidalgo, 11000, Ciudad de México, Mexico.

Insights

Preeclampsia (PE) in mothers alters lipid metabolism, leading to oxidized low-density lipoprotein (oxLDL). This impacts fetal development and increases neonates

Area of Science:

  • Obstetrics and Gynecology
  • Cardiovascular Medicine
  • Neonatology
  • Biochemistry

Background:

  • Preeclampsia (PE) is a pregnancy-specific multisystem disorder and a leading cause of maternal mortality.
  • The etiology of PE remains unknown, but altered lipid metabolism and oxidative stress are implicated.
  • Lipoproteins, including LDL and HDL, are susceptible to oxidative damage, generating harmful byproducts like malondialdehyde (MDA).

Purpose of the Study:

  • To review the impact of oxidized low-density lipoprotein (oxLDL) and high-density lipoprotein (HDL) in neonates born to mothers with preeclampsia.
  • To investigate how these lipoprotein alterations predispose neonates to adult-onset diseases.

Main Methods:

  • Literature review analyzing existing information on lipoprotein oxidation in preeclampsia and its neonatal consequences.
  • Focus on the role of oxidized LDL (oxLDL) in endothelial dysfunction and nitric oxide (NO) production.
  • Examination of the long-term health risks for neonates exposed to the preeclamptic intrauterine environment.

Main Results:

  • Oxidized LDL (oxLDL) interferes with endothelial nitric oxide synthase (eNOS) signaling, reducing vasodilation and causing endothelial dysfunction characteristic of PE.
  • Severe lipid damage in PE can generate toxic products like malondialdehyde (MDA).
  • Neonates of mothers with PE exhibit increased risks for cardiovascular diseases, stroke, developmental issues, and metabolic diseases later in life.

Conclusions:

  • Oxidative stress and subsequent lipoprotein modification in preeclampsia pose significant risks to fetal development.
  • Neonates exposed to PE in utero are predisposed to chronic diseases, including cardiovascular and metabolic disorders, in adulthood.
  • Further research is needed to understand the mechanisms linking maternal PE, neonatal lipoprotein alterations, and long-term health outcomes.

Related Concept Videos

Overview of Lipid Metabolism01:24

Overview of Lipid Metabolism

Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
2.6K
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
2.8K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
250